Document Detail

Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration.
MedLine Citation:
PMID:  20508510     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To determine the effect of intravitreal injection of ranibizumab on the corneal endothelium in patients with choroidal neovascularization in age-related macular degeneration. METHODS: Observational prospective case series study. Fifty-two eyes of 52 consecutive patients (29 men, 23 women; age range, 61-80 years) were evaluated. All participants received monthly intravitreal injections of (0.05 mL, 0.5 mg) ranibizumab for 3 consecutive months; the follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed, and the central corneal thickness was measured. RESULTS: There were no significant differences in the endothelial cell densities, coefficient of variation of cell sizes, and percentage of hexagonal cells values before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P = 0.987, P = 0.822, and P = 0.918, respectively). There was also no significant difference in central corneal thickness measurements before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P = 0.325). CONCLUSION: Repeated intravitreal injections of 0.5 mg of ranibizumab do not seem to cause substantial changes in the corneal endothelium at 6 months.
Consuelo Pérez-Rico; Javier Benítez-Herreros; María Castro-Rebollo; Yanira Gómez-Sangil; Francisco Germain; María Angeles Montes-Mollón; Miguel Angel Teus
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cornea     Volume:  29     ISSN:  1536-4798     ISO Abbreviation:  Cornea     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-27     Completed Date:  2010-10-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  849-52     Citation Subset:  IM    
Department of Ophthalmology, University Hospital Principe de Asturias, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal / administration & dosage*
Cell Count
Cell Size
Endothelium, Corneal / drug effects*,  pathology
Follow-Up Studies
Macular Degeneration / drug therapy*
Middle Aged
Prospective Studies
Vitreous Body
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/ranibizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bilateral Comparison of Conventional Epithelial Laser In Situ Keratomileusis and Lamellar Epithelial...
Next Document:  Significance of the Lacunar Hydration Pattern After Corneal Cross Linking.